TrialCancer2018
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Michael J Pishvaian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
43 papers cite it
this paperpooled ittrialcites it